NASONEX NASAL SPRAY

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

MOMETASONE FUROATE 50 MCG/DOSE

Verfügbar ab:

MERCK SHARP & DOHME ISRAEL LTD

ATC-Code:

D07AC13

Darreichungsform:

SOLUTION

Verabreichungsweg:

NASAL

Hergestellt von:

SCHERING-PLOUGH LAB.NV BELGIUM

Therapiegruppe:

MOMETASONE

Anwendungsgebiete:

In adults and children 3 years of age and older to treat the symptoms of seasonal or perennial rhinitis. In patients 12 years old and above who have a history of moderate to severe symptoms of seasonal allergic rhinitis prophylactic treatment with Nasonex Aqueous Nasal Spary is recommended 2- 4 weeks prior to the anticipated start of the pollen season.

Berechtigungsdatum:

2013-03-01